Skip to main content
Premium Trial:

Request an Annual Quote

Twist Bioscience, Australian Research Council Partner on Synthetic Biology R&D

NEW YORK – Twist Bioscience and the Australian Research Council Centre of Excellence in Synthetic Biology (ARCCoESB) said on Tuesday that they have partnered on research and development.

Under the agreement, ARCCoESB members will be able to order Twist DNA synthesis products at an early stage. "We gain access to the capabilities and availability of CoESB members to shape new products, while they are able to gain early access to upcoming products within Twist's synthetic biology product program," Twist CEO and Cofounder Emily Leproust said in a statement.

Financial and other details of the deal were not disclosed.

ARCCoESB was established in 2020, bringing together nine Australian universities and partners — including biotech startups, government departments, and other organizations — with the aim of creating an environmentally sustainable processing industry.

South San Francisco, California-based Twist Bioscience makes synthetic DNA using silicon chips for a variety of applications, including synthetic biology, drug discovery and development, next-generation sequencing target enrichment, and DNA-based data storage.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.